(Q52591499)

4 May 2018

title

Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. (English)

1 reference

4 May 2018

0 references

1 reference

8

1 reference

4 May 2018

author name string

Y Benesová

1

1 reference

4 May 2018

A Vasku

2

1 reference

4 May 2018

H Novotná

3

1 reference

4 May 2018

J Litzman

4

1 reference

4 May 2018

P Stourac

5

1 reference

4 May 2018

M Beránek

6

1 reference

4 May 2018

Z Kadanka

7

1 reference

4 May 2018

publication date

19 January 2009

1 reference

4 May 2018

Multiple Sclerosis Journal

published in

1 reference

4 May 2018

volume

15

1 reference

4 May 2018

issue

3

1 reference

4 May 2018

page(s)

316-322

1 reference

4 May 2018

What do we know about the mechanism of action of disease-modifying treatments in MS?

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Predicting the course of relapsing-remitting MS using longitudinal disability curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Matrix metalloproteinase-9 and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Metalloproteinases and their tissue inhibitors in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Matrix metalloproteinases: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Differential expression of tissue inhibitor of metalloproteinases-3 in cultured astrocytes and neurons regulates the activation of matrix metalloproteinase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508099482

21 January 2018

Identifiers

DOI

10.1177/1352458508099482

1 reference

4 May 2018

1 reference

4 May 2018